Mirador Capital Partners LP Athira Pharma, Inc. Transaction History
Mirador Capital Partners LP
- $546 Million
- Q3 2024
A detailed history of Mirador Capital Partners LP transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Mirador Capital Partners LP holds 19,454 shares of ATHA stock, worth $8,754. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,454
Previous 20,040
2.92%
Holding current value
$8,754
Previous $53,000
84.91%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding ATHA
# of Institutions
75Shares Held
23.1MCall Options Held
73.4KPut Options Held
97.8K-
Perceptive Advisors LLC New York, NY5.4MShares$2.43 Million0.41% of portfolio
-
Baker Bros. Advisors LP New York, NY3.15MShares$1.42 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$735,4940.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$671,7562.57% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$671,7560.29% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $17M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...